{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T17:00:54Z","timestamp":1785776454867,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jns.2025.123392","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:08:04Z","timestamp":1736377684000},"page":"123392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies"],"prefix":"10.1016","volume":"469","author":[{"given":"Viviana","family":"Nociti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Romozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Annovazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fantozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Tortorella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vercellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Lorefice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia Teresa","family":"Maniscalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ronzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Marcello","family":"Solaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catello","family":"Vollono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jns.2025.123392_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.msard.2012.10.003","article-title":"Migraine and multiple sclerosis: epidemiology and approach to treatment","volume":"2","author":"Gelfand","year":"2013","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"17","key":"10.1016\/j.jns.2025.123392_bb0010","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1080\/14656566.2023.2262384","article-title":"Migraine in multiple sclerosis patients: potential links and treatment approach","volume":"24","author":"Gklinos","year":"2023","journal-title":"Expert. Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.jns.2025.123392_bb0015","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.jns.2025.123392_bb0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2018.07.005","article-title":"Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis","volume":"323","author":"Rossetti","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.jns.2025.123392_bb0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/HJH.0000000000001649","article-title":"Endogenous calcitonin gene-related peptide suppresses ischemic brain injuries and progression of cognitive decline","volume":"36","author":"Zhai","year":"2018","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.jns.2025.123392_bb0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00409-9","article-title":"Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions","volume":"21","author":"Al-Hassany","year":"2022","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.123392_bb0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40263-021-00893-y","article-title":"Long-term effectiveness of three anti-CGRP monoclonal antibodies in resistant chronic migraine patients based on the MIDAS score","volume":"36","author":"Iannone","year":"2022","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jns.2025.123392_bb0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","article-title":"Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis","volume":"23","author":"Andreou","year":"2022","journal-title":"J. Headache Pain"},{"issue":"12","key":"10.1016\/j.jns.2025.123392_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/03331024241262751","article-title":"An evolving machine-learning-based algorithm to early predict response to anti-CGRP monoclonal antibodies in patients with migraine","volume":"44","author":"Romozzi","year":"2024","journal-title":"Cephalalgia"},{"issue":"13","key":"10.1016\/j.jns.2025.123392_bb0050","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1177\/13524585221096353","article-title":"Anti-CGRP therapies for migraine in multiple sclerosis patients","volume":"28","author":"Gonzalez-Martinez","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jns.2025.123392_bb0055","article-title":"Use of calcitonin gene-related peptide monoclonal antibodies for the treatment of migraines in individuals with multiple sclerosis","author":"Mason","year":"2023","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.jns.2025.123392_bb0060","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16450","article-title":"Association of anti-calcitonin gene-related peptide with other monoclonal antibodies for different diseases: a multicenter, prospective, cohort study","author":"Iannone","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2025.123392_bb0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2025.123392_bb0070","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition (2018). Cephalalgia 38 (1):1\u2013211. doi:https:\/\/doi.org\/10.1177\/0333102417738202.","DOI":"10.1177\/0333102417738202"},{"issue":"1","key":"10.1016\/j.jns.2025.123392_bb0075","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10072-011-0519-2","article-title":"Quality of life of multiple sclerosis patients with comorbid migraine","volume":"32","author":"Villani","year":"2011","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2025.123392_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/epi.17147","article-title":"Not your usual drug-drug interactions: monoclonal antibody-based therapeutics may interact with antiseizure medications","volume":"63","author":"Berman","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2025.123392_bb0085","article-title":"Tolerability of calcitonin gene-related peptide monoclonal antibodies and other monoclonal antibodies in adults with concurrent migraine and other medical conditions","volume":"7","author":"Weber","year":"2024","journal-title":"Cephalalgia Rep."},{"issue":"12","key":"10.1016\/j.jns.2025.123392_bb0090","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/ene.14432","article-title":"Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study","volume":"27","author":"Schriefer","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2025.123392_bb0095","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1007\/s10072-023-06838-1","article-title":"Real-world annualized relapse rates from contemporary multiple sclerosis clinics in the UK: a retrospective multicentre cohort study","volume":"44","author":"Papathanasiou","year":"2023","journal-title":"Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jns.2025.123392_bb0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jneuroim.2014.03.008","article-title":"Involvement of calcitonin gene-related peptide and receptor component protein in experimental autoimmune encephalomyelitis","volume":"271","author":"Sardi","year":"2014","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.jns.2025.123392_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/biom12020199","article-title":"Cerebrospinal fluid \u03b1-calcitonin gene-related peptide: a comparison between Alzheimer\u2019s disease and multiple sclerosis","volume":"12","author":"Papiri","year":"2022","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.jns.2025.123392_bb0110","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2174\/1871527322666230403130540","article-title":"Alpha calcitonin gene-related peptide, neuropeptide Y, and substance P as biomarkers for diagnosis and disease activity and severity in multiple sclerosis","volume":"23","author":"Al-Keilani","year":"2024","journal-title":"CNS Neurol. Disord. Drug Targets"},{"issue":"1","key":"10.1016\/j.jns.2025.123392_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","article-title":"Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-Centre retrospective observational study","volume":"24","author":"Ihara","year":"2023","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2025.123392_bb0120","doi-asserted-by":"crossref","DOI":"10.4081\/cc.2024.15762","article-title":"Prospective evaluation of aura during anti-calcitonin gene-related peptide monoclonal antibody therapy after 52 weeks of treatment","volume":"34","author":"Romozzi","year":"2024","journal-title":"Confinia Cephalalgica"},{"issue":"2","key":"10.1016\/j.jns.2025.123392_bb0125","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","article-title":"Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system","volume":"40","author":"Silberstein","year":"2023","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.jns.2025.123392_bb0130","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s40122-022-00440-7","article-title":"Inpatient constipation among migraine patients prescribed anti-calcitonin gene-related peptide monoclonal antibodies and standard of care antiepileptic drugs: a retrospective cohort study in a United States electronic health record database","volume":"11","author":"Chomistek","year":"2022","journal-title":"Pain Ther."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25000097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X25000097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T03:45:40Z","timestamp":1738381540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X25000097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":26,"alternative-id":["S0022510X25000097"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2025.123392","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2025.123392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123392"}}